FAKTOR-OPTIONSSCHEIN - GENMAB | Real-time Boerse Frankfurt Warrants 03:48:10 2024-06-03 EDT | ||
| 9.55 EUR | +5.64% |
|
| 1 month | -8.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 9.55 | +5.64% |
| 24-05-31 | 9.04 | +2.61% |
| 24-05-30 | 8.81 | +2.56% |
| 24-05-29 | 8.59 | -2.50% |
| 24-05-28 | 8.81 | -2.97% |
Real-time Boerse Frankfurt Warrants
Last update June 03, 2024 at 03:48 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW9NBB |
| ISIN | DE000SW9NBB1 |
| Date issued | 2024-04-29 |
| Strike | 1,916 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.17 € |
|---|---|
| Lowest since issue | 8.49 € |
| Spread | 0.06 € |
| Spread % | 0.63% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,937
DKK
Average target price
2,464
DKK
Spread / Average Target
+27.21%
- Stock Market
- Certificates
- Certificat
